“Microdosing” is not a medical term and is not a licensed way to use Mounjaro (tirzepatide) or Wegovy (semaglutide). There are no clinical trials of taking a fraction of a pen dose, and the pens are not designed to deliver partial doses accurately. However, lower licensed doses do have trial evidence, and slower titration, staying on a lower licensed maintenance dose, or a prescriber-led step-down are all legitimate options. If side effects or cost are the concern, speak to your prescriber or pharmacist rather than adjusting the dose yourself.
The phrase has no agreed definition. In practice it covers several quite different things, and it helps to separate them because some are ordinary prescribing decisions and some carry real risk.
| What people mean | What it involves | Licensed or evidence-based? |
|---|---|---|
| Staying on a low licensed dose | Remaining on a standard dose such as Mounjaro 5mg or Wegovy 1mg rather than increasing | Yes Licensed doses with trial data |
| Slower titration | Spending longer on each step before increasing | Yes Where a prescriber agrees |
| Taking part of a pen dose | Using less than the dose the pen is set to deliver | No No evidence; not how the pens are designed to be used |
| Stretching a pen | Using one pen beyond its in-use window by taking smaller amounts | No Stability, accuracy and contamination concerns |
| Unlicensed vials or “research” products | Buying non-pharmacy products and drawing up small doses | No Not authorised medicines in the UK |
The rest of this guide focuses on the last three rows, because those are the practices that carry risk. The first two are covered in the dose schedule guides for Mounjaro, Wegovy, the Wegovy pill and Foundayo.
Why Are People Tempted?- Cost. Weight-loss medicines are a monthly expense and higher doses can cost more, so making a pen last longer looks like a saving. See our guides on Mounjaro costs and Wegovy cost in the UK.
- Side effects. Nausea, constipation, reflux and fatigue are common, particularly after a dose increase. See our guides on nausea and constipation.
- Fear of a “high dose”. Some people simply want the lowest dose that works.
- Social media. Posts promoting tiny doses are shared as personal success stories, without trial data behind them.
All of these are reasonable concerns. The problem is the solution, not the motivation.
What the Clinical Evidence Actually ShowsLicensed lower doses work, in a dose-dependent way
The strongest relevant evidence is dose-response data from licensed doses. In the SURMOUNT-1 trial of tirzepatide in adults with obesity, average weight loss at 72 weeks rose with each licensed dose. Lower licensed doses therefore produce meaningful weight loss, but less on average than higher ones, and individual responses vary widely.
Mounjaro (tirzepatide) in adults with obesity, SURMOUNT-1, treatment-regimen estimand. These are averages of whole licensed doses delivered by the pen, not partial doses.
| Mounjaro dose (SURMOUNT-1) | Average weight loss at 72 weeks | What this tells us |
|---|---|---|
| 5mg weekly | 15.0% | A licensed dose with substantial average benefit |
| 10mg weekly | 19.5% | Further average benefit over 5mg |
| 15mg weekly | 20.9% | Greatest average benefit, with more people reporting digestive effects |
This is the evidence people are often pointing to when they say a lower dose can work, and it is a fair point. But it is evidence about whole licensed doses delivered by a pen built to give them. It says nothing about a quarter of a pen click or an uncertain amount drawn from a vial. For how the licensed steps work, see our Mounjaro tolerance guide and Wegovy tolerance guide.
There is no trial evidence for fractions of a dose
No randomised trial has tested taking a fraction of a licensed dose of tirzepatide or semaglutide in the pen formulations used in the UK. That means we do not know the effect on weight, blood sugar, appetite or side effects, how long any effect would last, or whether it is safe. Anecdotes cannot answer those questions, because people who feel better tend to post and people who do not, do not.
Pens are designed to deliver set doses
The Mounjaro KwikPen and the Wegovy FlexTouch pen are built to deliver specific, labelled doses. They are not designed to deliver arbitrary smaller amounts, and the instructions for use do not describe it. Trying to do so risks an inaccurate dose, and an inaccurate dose means an unpredictable effect. Our injection technique guide shows how the pens are meant to be used.
Pens have an in-use window
Once started, a Mounjaro pen should be used within 30 days and a Wegovy pen within 6 weeks, after which any remaining medicine should be discarded. These limits exist because of stability and the risk of contamination with repeated use. Making a pen last longer by taking smaller amounts means using medicine beyond the period it has been shown to remain suitable. Our storage guides for Mounjaro and Wegovy cover this in detail.
| Pen | In-use window once started | Why it matters |
|---|---|---|
| Mounjaro KwikPen | 30 days | Stability and contamination risk beyond this period |
| Wegovy FlexTouch | 6 weeks | Stability and contamination risk beyond this period |
Important
Never reuse needles or share pens, and never draw medicine out of a pen into a syringe. These practices are unsafe and are not covered by any product instructions. Always follow the patient information leaflet supplied with your pen.
Uneven dosing can make side effects worse, not better
Many side effects relate to the size of a dose and to changes in dose. Very small, irregular amounts can make your blood levels swing, which may make symptoms less predictable rather than more manageable. Stable levels are part of why these medicines are given weekly at fixed doses. If you are struggling with side effects, our Mounjaro, Wegovy and Foundayo side effects guides explain what to expect and what helps.
The Risks of Unlicensed Vials and “Research” ProductsSome of the most aggressive promotion of microdosing involves unlicensed vials sold online as “research chemicals”, or products that must be reconstituted and measured with a syringe. In the UK these are not authorised medicines. Their contents, strength, sterility and storage history cannot be assured, and the person using them has to measure tiny volumes themselves, where small errors become large dose errors.
Medicines regulators have repeatedly warned the public about counterfeit and unlicensed weight-loss injections. Our guide to spotting fake weight-loss injections explains the MHRA's advice. As a rule, a prescription-only medicine should come from a registered pharmacy after a clinical consultation. You can check any pharmacy on the General Pharmaceutical Council register, and our Is Happy Pharmacy a genuine UK pharmacy? guide shows how, including our own GPhC register entry. We explain why it matters in our guides on buying Mounjaro and Wegovy from a GPhC-registered pharmacy.
When to get help
If you have used an unlicensed product and feel unwell, seek medical advice promptly. Severe persistent abdominal pain, repeated vomiting, signs of dehydration, an allergic reaction or symptoms of very low blood sugar need urgent help.
Most people who ask about microdosing want one of three things: fewer side effects, lower cost, or the lowest effective dose. There are legitimate ways to pursue each.
| If your concern is… | Licensed option to discuss with your prescriber | See |
|---|---|---|
| Side effects after an increase | Stay at the current dose for longer before stepping up, or step back to the previous dose, under prescriber guidance | Mounjaro dose schedule |
| Side effects in general | Practical and dietary measures | Nausea guide · Constipation guide |
| Cost | Staying on a lower licensed maintenance dose where it controls your weight; comparing total cost over the whole course, not just the first month | Is Mounjaro worth the money? · Is Wegovy worth the money? |
| Wanting the lowest effective dose | A prescriber-led review of whether a lower licensed dose is enough for you | Mounjaro maintenance · Maintaining after Wegovy |
| Planning to come off treatment | A planned conversation about options, as there is no established taper schedule | All weight loss guides |
Slower titration
Both Mounjaro and Wegovy start at low doses and increase in steps. If a step up brings troublesome side effects, your prescriber may keep you on the current dose for longer. This is a standard, supported approach. Our dose schedule guides for Mounjaro and Wegovy explain the usual steps, and our missed Mounjaro dose guide explains what to do if a dose is delayed.
Staying on a lower licensed dose
Higher is not always better. Some people reach a good response at a lower licensed dose, and for them there is no clinical reason to increase simply because a higher dose exists. The decision should reflect your progress, tolerability and goals, agreed with your prescriber at review. It can also keep costs down without taking any risks with the pen. If your weight has stalled, see our Mounjaro, Wegovy and Foundayo plateau guides before deciding to change dose.
Reducing cost safely
Cost is a legitimate concern and worth raising openly. The cheapest first month is not always the cheapest course: what matters is the total cost of the dose you actually need over the whole treatment. Our cost guides for Mounjaro and Wegovy are a good starting point, and if you take higher-strength Wegovy see our Wegovy 7.2mg guide.
Maintenance and StoppingWeight tends to return when treatment stops, so a planned approach works better than an improvised one. Because there is no evidence that taking tiny amounts maintains weight, “microdosing” should not be seen as a way to taper off. If you are thinking about coming off treatment, speak to your prescriber, and see our guides on maintaining weight loss after Wegovy and Foundayo. Protecting muscle matters too: see our Mounjaro, Wegovy, Wegovy pill and Foundayo muscle preservation guides.
What About Wegovy Pills and Foundayo?The Wegovy pill and Foundayo (orforglipron) are daily tablets, so the pen-related issues above do not apply in the same way. The same principle holds, however: each is licensed at specific doses with its own titration steps, and there is no evidence for splitting tablets or altering the schedule. See how to take the Wegovy pill and how to take Foundayo. If you are struggling with side effects, speak to your prescriber about the licensed options. Not sure which treatment suits you? Our Wegovy v Mounjaro v Wegovy pill decision guide compares them.
Questions to Ask Your Prescriber- Is my current dose still right for me, or could a lower licensed dose be enough?
- If I have side effects, can we step back or slow the next increase?
- What is the total cost of the dose I need over the next six months?
- What would a sensible plan look like if I decide to stop?
The bottom line
The idea behind microdosing, getting the benefit with fewer side effects and less cost, is reasonable. The method is not. Lower licensed doses, slower titration and prescriber-led reviews can achieve much of the same, with evidence and safety behind them. Check your eligibility with our BMI calculator or see our weight loss consultation.
Talk to a Pharmacist About the Right Dose for You
Our GPhC-registered pharmacy team can review your progress, side effects and goals, so you stay on a safe, licensed dose.
Start Your Free Online Consultation → Use code SWITCH10 if you're switching from another provider Happy Pharmacy is a GPhC-registered pharmacy (No. 9013192) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Mounjaro® (tirzepatide) KwikPen: UK Summary of Product Characteristics and patient information leaflet, electronic Medicines Compendium (emc).
- Wegovy® (semaglutide) FlexTouch: UK Summary of Product Characteristics and patient information leaflet, emc.
- Foundayo® (orforglipron) UK Summary of Product Characteristics, emc.
- MHRA. Counterfeit and unlicensed weight-loss medicines: public safety information.
- General Pharmaceutical Council. Register of pharmacies: how to check a pharmacy is registered.
- NICE. Tirzepatide for managing overweight and obesity (TA1026).